25 XP   0   0   10

Silence Therapeutics PLC
Buy, Hold or Sell?

Let's analyse Silence Therapeutics PLC together

PenkeI guess you are interested in Silence Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Silence Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Silence Therapeutics PLC

I send you an email if I find something interesting about Silence Therapeutics PLC.

Quick analysis of Silence Therapeutics PLC (30 sec.)










What can you expect buying and holding a share of Silence Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.18
Expected worth in 1 year
$-0.24
How sure are you?
29.4%

+ What do you gain per year?

Total Gains per Share
$-0.42
Return On Investment
-1.9%

For what price can you sell your share?

Current Price per Share
$21.60
Expected price per share
$16.20 - $27.72
How sure are you?
50%

1. Valuation of Silence Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)

$21.60

Intrinsic Value Per Share

$-3.85 - $-4.35

Total Value Per Share

$-3.67 - $-4.17

2. Growth of Silence Therapeutics PLC (5 min.)




Is Silence Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$21.5m$17.4m$3.2m15.8%

How much money is Silence Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$13.6m-$12.7m-$876.3k-6.4%
Net Profit Margin-296.4%-240.4%--

How much money comes from the company's main activities?

3. Financial Health of Silence Therapeutics PLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#597 / 1031

Most Revenue
#311 / 1031

Most Profit
#649 / 1031

Most Efficient
#703 / 1031

What can you expect buying and holding a share of Silence Therapeutics PLC? (5 min.)

Welcome investor! Silence Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Silence Therapeutics PLC.

What can you expect buying and holding a share of Silence Therapeutics PLC?

First you should know what it really means to hold a share of Silence Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Silence Therapeutics PLC is $21.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Silence Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Silence Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.18. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Silence Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-0.7%-0.23-1.1%-0.27-1.3%-0.23-1.1%-0.23-1.1%
Usd Book Value Change Per Share-0.36-1.7%-0.10-0.5%0.090.4%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.36-1.7%-0.10-0.5%0.090.4%0.010.0%0.010.0%
Usd Price Per Share17.37-9.72-14.03-13.41-13.41-
Price to Earnings Ratio-28.38--12.45--13.79--13.71--13.71-
Price-to-Total Gains Ratio-48.04--22.43--60.37--43.77--43.77-
Price to Book Ratio95.96-36.09-29.91-38.86-38.86-
Price-to-Total Gains Ratio-48.04--22.43--60.37--43.77--43.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.6
Number of shares46
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.01
Usd Total Gains Per Share-0.100.01
Gains per Quarter (46 shares)-4.810.49
Gains per Year (46 shares)-19.221.96
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-19-2902-8
20-38-4804-6
30-58-6706-4
40-77-8608-2
50-96-1050100
60-115-1240122
70-135-1430144
80-154-1620166
90-173-1810188
100-192-20002010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.08.01.025.0%5.09.03.029.4%5.09.03.029.4%5.09.03.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share1.03.00.025.0%3.08.01.025.0%5.09.03.029.4%5.09.03.029.4%5.09.03.029.4%

Fundamentals of Silence Therapeutics PLC

About Silence Therapeutics PLC

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-03-22 04:00:10.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Silence Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Silence Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of -686.6% means that $-6.87 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Silence Therapeutics PLC:

  • The MRQ is -686.6%. The company is making a huge loss. -2
  • The TTM is -296.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-686.6%TTM-296.4%-390.3%
TTM-296.4%YOY-240.4%-56.0%
TTM-296.4%5Y-328.6%+32.2%
5Y-328.6%10Y-328.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-686.6%-159.2%-527.4%
TTM-296.4%-202.3%-94.1%
YOY-240.4%-263.0%+22.6%
5Y-328.6%-452.4%+123.8%
10Y-328.6%-589.0%+260.4%
1.1.2. Return on Assets

Shows how efficient Silence Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • -15.4% Return on Assets means that Silence Therapeutics PLC generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Silence Therapeutics PLC:

  • The MRQ is -15.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-11.5%-3.9%
TTM-11.5%YOY-10.4%-1.0%
TTM-11.5%5Y-9.3%-2.1%
5Y-9.3%10Y-9.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-12.5%-2.9%
TTM-11.5%-12.2%+0.7%
YOY-10.4%-11.2%+0.8%
5Y-9.3%-13.3%+4.0%
10Y-9.3%-14.6%+5.3%
1.1.3. Return on Equity

Shows how efficient Silence Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • -84.5% Return on Equity means Silence Therapeutics PLC generated $-0.85 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Silence Therapeutics PLC:

  • The MRQ is -84.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -68.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-84.5%TTM-68.0%-16.5%
TTM-68.0%YOY-68.9%+0.9%
TTM-68.0%5Y-56.6%-11.4%
5Y-56.6%10Y-56.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-84.5%-16.0%-68.5%
TTM-68.0%-15.8%-52.2%
YOY-68.9%-13.9%-55.0%
5Y-56.6%-18.2%-38.4%
10Y-56.6%-19.1%-37.5%

1.2. Operating Efficiency of Silence Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Silence Therapeutics PLC is operating .

  • Measures how much profit Silence Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of -716.0% means the company generated $-7.16  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Silence Therapeutics PLC:

  • The MRQ is -716.0%. The company is operating very inefficient. -2
  • The TTM is -331.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-716.0%TTM-331.4%-384.6%
TTM-331.4%YOY-298.6%-32.9%
TTM-331.4%5Y-371.0%+39.6%
5Y-371.0%10Y-371.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-716.0%-299.5%-416.5%
TTM-331.4%-208.5%-122.9%
YOY-298.6%-280.2%-18.4%
5Y-371.0%-459.9%+88.9%
10Y-371.0%-596.9%+225.9%
1.2.2. Operating Ratio

Measures how efficient Silence Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.34 means that the operating costs are $7.34 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Silence Therapeutics PLC:

  • The MRQ is 7.336. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.300. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.336TTM4.300+3.036
TTM4.300YOY3.986+0.315
TTM4.3005Y4.024+0.276
5Y4.02410Y4.0240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3362.817+4.519
TTM4.3003.181+1.119
YOY3.9863.609+0.377
5Y4.0245.554-1.530
10Y4.0247.396-3.372

1.3. Liquidity of Silence Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Silence Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.56 means the company has $4.56 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Silence Therapeutics PLC:

  • The MRQ is 4.560. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.585. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.560TTM4.585-0.026
TTM4.585YOY4.357+0.229
TTM4.5855Y5.168-0.583
5Y5.16810Y5.1680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5603.987+0.573
TTM4.5854.440+0.145
YOY4.3575.569-1.212
5Y5.1686.158-0.990
10Y5.1686.492-1.324
1.3.2. Quick Ratio

Measures if Silence Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 4.10 means the company can pay off $4.10 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Silence Therapeutics PLC:

  • The MRQ is 4.101. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.598. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.101TTM4.598-0.497
TTM4.598YOY4.145+0.453
TTM4.5985Y4.715-0.117
5Y4.71510Y4.7150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1013.653+0.448
TTM4.5984.158+0.440
YOY4.1455.515-1.370
5Y4.7156.012-1.297
10Y4.7156.206-1.491

1.4. Solvency of Silence Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Silence Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Silence Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.82 means that Silence Therapeutics PLC assets are financed with 81.8% credit (debt) and the remaining percentage (100% - 81.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Silence Therapeutics PLC:

  • The MRQ is 0.818. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.827. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.818TTM0.827-0.008
TTM0.827YOY0.883-0.056
TTM0.8275Y0.804+0.023
5Y0.80410Y0.8040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8180.336+0.482
TTM0.8270.330+0.497
YOY0.8830.267+0.616
5Y0.8040.367+0.437
10Y0.8040.378+0.426
1.4.2. Debt to Equity Ratio

Measures if Silence Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 450.3% means that company has $4.50 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Silence Therapeutics PLC:

  • The MRQ is 4.503. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.913. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.503TTM4.913-0.410
TTM4.913YOY6.814-1.901
TTM4.9135Y5.279-0.366
5Y5.27910Y5.2790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5030.376+4.127
TTM4.9130.398+4.515
YOY6.8140.334+6.480
5Y5.2790.431+4.848
10Y5.2790.476+4.803

2. Market Valuation of Silence Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Silence Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Silence Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -28.38 means the investor is paying $-28.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Silence Therapeutics PLC:

  • The EOD is -35.291. Based on the earnings, the company is expensive. -2
  • The MRQ is -28.380. Based on the earnings, the company is expensive. -2
  • The TTM is -12.454. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-35.291MRQ-28.380-6.911
MRQ-28.380TTM-12.454-15.926
TTM-12.454YOY-13.788+1.334
TTM-12.4545Y-13.709+1.254
5Y-13.70910Y-13.7090.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-35.291-2.697-32.594
MRQ-28.380-2.422-25.958
TTM-12.454-2.709-9.745
YOY-13.788-4.116-9.672
5Y-13.709-6.257-7.452
10Y-13.709-6.478-7.231
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Silence Therapeutics PLC:

  • The EOD is -42.860. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -34.466. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.945. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-42.860MRQ-34.466-8.393
MRQ-34.466TTM-15.945-18.522
TTM-15.945YOY-11.327-4.618
TTM-15.9455Y-17.390+1.445
5Y-17.39010Y-17.3900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-42.860-3.344-39.516
MRQ-34.466-2.939-31.527
TTM-15.945-3.486-12.459
YOY-11.327-5.592-5.735
5Y-17.390-8.464-8.926
10Y-17.390-8.872-8.518
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Silence Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 95.96 means the investor is paying $95.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Silence Therapeutics PLC:

  • The EOD is 119.324. Based on the equity, the company is expensive. -2
  • The MRQ is 95.956. Based on the equity, the company is expensive. -2
  • The TTM is 36.091. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD119.324MRQ95.956+23.368
MRQ95.956TTM36.091+59.865
TTM36.091YOY29.915+6.177
TTM36.0915Y38.860-2.769
5Y38.86010Y38.8600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD119.3242.198+117.126
MRQ95.9562.042+93.914
TTM36.0912.121+33.970
YOY29.9152.907+27.008
5Y38.8603.682+35.178
10Y38.8604.114+34.746
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Silence Therapeutics PLC.

3.1. Institutions holding Silence Therapeutics PLC

Institutions are holding 44.593% of the shares of Silence Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Lombard Odier Asset Management USA Corp10.03150.98973879173-178759-4.4052
2023-12-31Lombard Odier Asset Management (EU) Ltd9.34293.636436128771689654.9062
2023-12-31Artal Group S A7.7581.7323300000050000020
2023-12-31TCG Crossover Management, LLC5.44324.0547210487500
2023-12-31Deep Track Capital, LP5.04681.1321195158000
2023-09-30Bvf Inc3.90070.3998150841600
2023-12-31Aquilo Capital Management, LLC2.697911.29421043284-268949-20.4955
2023-12-31Vivo Capital, LLC1.31940.72565102045102040
2023-12-31Logos Global Management LP1.03440.64864000004000000
2023-12-31M28 Capital Management LP0.94085.235236380000
2023-12-31Parkman Healthcare Partners LLC0.60240.56992329424006320.7711
2023-12-31HSBC Holdings PLC0.45990.002717783400
2023-12-31UBS O'Connor LLC0.2410.116493198-5128-5.2153
2023-12-31UBS Group AG0.18090.0004699468331.2053
2023-12-31Morgan Stanley - Brokerage Accounts0.16240.000162808951117.8453
2023-12-31Citigroup Inc0.15080.00075833300
2023-12-31Woodline Partners LP0.12740.009349272-117380-70.4342
2023-09-30Schonfeld Strategic Advisors LLC0.120.003546400-600-1.2766
2023-12-31Renaissance Technologies Corp0.07010.000727102271020
2023-12-31Blair William & Co0.06610.001525548-13438-34.4688
Total 49.696630.553819217592+1072424+5.6%

3.2. Funds holding Silence Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-08-31Galileo - Biotech Innovation Fund S USD0.13431.47245319700
2024-01-31Monega ARIAD Innovation R0.0980.57653880500
2024-01-31Fidelity Nasdaq Composite Index0.05660.00352242700
2024-02-29ActivePassive International Equity ETF0.00670.02612662240.9098
2023-12-31Lazard Genetic Therapies ADR0.00011.21743600
Total 0.29573.2959117127+24+0.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Silence Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.362-0.104-71%0.092-494%0.011-3496%0.011-3496%
Book Value Per Share--0.1810.377-52%0.376-52%0.411-56%0.411-56%
Current Ratio--4.5604.585-1%4.357+5%5.168-12%5.168-12%
Debt To Asset Ratio--0.8180.827-1%0.883-7%0.804+2%0.804+2%
Debt To Equity Ratio--4.5034.913-8%6.814-34%5.279-15%5.279-15%
Dividend Per Share----0%-0%-0%-0%
Eps---0.153-0.234+53%-0.275+80%-0.231+51%-0.231+51%
Free Cash Flow Per Share---0.126-0.218+73%-0.311+147%-0.129+2%-0.129+2%
Free Cash Flow To Equity Per Share---0.021-0.089+329%-0.019-7%0.086-124%0.086-124%
Gross Profit Margin--1.0001.0000%1.0000%0.968+3%0.968+3%
Intrinsic Value_10Y_max---4.354--------
Intrinsic Value_10Y_min---3.853--------
Intrinsic Value_1Y_max---0.626--------
Intrinsic Value_1Y_min---0.615--------
Intrinsic Value_3Y_max---1.735--------
Intrinsic Value_3Y_min---1.660--------
Intrinsic Value_5Y_max---2.671--------
Intrinsic Value_5Y_min---2.492--------
Market Cap1004449680.000-106%2064371799.420766275323.855+169%652601652.625+216%697586190.542+196%697586190.542+196%
Net Profit Margin---6.866-2.964-57%-2.404-65%-3.286-52%-3.286-52%
Operating Margin---7.160-3.314-54%-2.986-58%-3.710-48%-3.710-48%
Operating Ratio--7.3364.300+71%3.986+84%4.024+82%4.024+82%
Pb Ratio119.324+20%95.95636.091+166%29.915+221%38.860+147%38.860+147%
Pe Ratio-35.291-24%-28.380-12.454-56%-13.788-51%-13.709-52%-13.709-52%
Price Per Share21.600+20%17.3709.723+79%14.034+24%13.412+30%13.412+30%
Price To Free Cash Flow Ratio-42.860-24%-34.466-15.945-54%-11.327-67%-17.390-50%-17.390-50%
Price To Total Gains Ratio-59.733-24%-48.035-22.435-53%-60.372+26%-43.769-9%-43.769-9%
Quick Ratio--4.1014.598-11%4.145-1%4.715-13%4.715-13%
Return On Assets---0.154-0.115-25%-0.104-32%-0.093-39%-0.093-39%
Return On Equity---0.845-0.680-20%-0.689-18%-0.566-33%-0.566-33%
Total Gains Per Share---0.362-0.104-71%0.092-494%0.011-3496%0.011-3496%
Usd Book Value--21513690.00020786262.300+3%17492648.850+23%21159940.659+2%21159940.659+2%
Usd Book Value Change Per Share---0.362-0.104-71%0.092-494%0.011-3496%0.011-3496%
Usd Book Value Per Share--0.1810.377-52%0.376-52%0.411-56%0.411-56%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.153-0.234+53%-0.275+80%-0.231+51%-0.231+51%
Usd Free Cash Flow---14973780.600-12429045.450-17%-14477893.200-3%-6349117.818-58%-6349117.818-58%
Usd Free Cash Flow Per Share---0.126-0.218+73%-0.311+147%-0.129+2%-0.129+2%
Usd Free Cash Flow To Equity Per Share---0.021-0.089+329%-0.019-7%0.086-124%0.086-124%
Usd Market Cap1004449680.000-106%2064371799.420766275323.855+169%652601652.625+216%697586190.542+196%697586190.542+196%
Usd Price Per Share21.600+20%17.3709.723+79%14.034+24%13.412+30%13.412+30%
Usd Profit---18185061.600-13648575.150-25%-12772255.050-30%-10779112.059-41%-10779112.059-41%
Usd Revenue--2648518.2008004543.750-67%5520690.450-52%4274013.494-38%4274013.494-38%
Usd Total Gains Per Share---0.362-0.104-71%0.092-494%0.011-3496%0.011-3496%
 EOD+3 -5MRQTTM+14 -19YOY+14 -195Y+12 -2210Y+12 -22

4.2. Fundamental Score

Let's check the fundamental score of Silence Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-35.291
Price to Book Ratio (EOD)Between0-1119.324
Net Profit Margin (MRQ)Greater than0-6.866
Operating Margin (MRQ)Greater than0-7.160
Quick Ratio (MRQ)Greater than14.101
Current Ratio (MRQ)Greater than14.560
Debt to Asset Ratio (MRQ)Less than10.818
Debt to Equity Ratio (MRQ)Less than14.503
Return on Equity (MRQ)Greater than0.15-0.845
Return on Assets (MRQ)Greater than0.05-0.154
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Silence Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.626
Ma 20Greater thanMa 5023.895
Ma 50Greater thanMa 10022.573
Ma 100Greater thanMa 20018.386
OpenGreater thanClose22.090
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in GBP. All numbers in thousands.

Summary
Total Assets93,822
Total Liabilities76,772
Total Stockholder Equity17,050
 As reported
Total Liabilities 76,772
Total Stockholder Equity+ 17,050
Total Assets = 93,822

Assets

Total Assets93,822
Total Current Assets81,021
Long-term Assets12,801
Total Current Assets
Cash And Cash Equivalents 54,031
Net Receivables 18,833
Total Current Assets  (as reported)81,021
Total Current Assets  (calculated)72,864
+/- 8,157
Long-term Assets
Property Plant Equipment 1,813
Goodwill 7,840
Long Term Investments 284
Intangible Assets 284
Long-term Assets Other 2,580
Long-term Assets  (as reported)12,801
Long-term Assets  (calculated)12,801
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,769
Long-term Liabilities59,003
Total Stockholder Equity17,050
Total Current Liabilities
Short-term Debt 179
Accounts payable 2,629
Other Current Liabilities 9,800
Total Current Liabilities  (as reported)17,769
Total Current Liabilities  (calculated)12,608
+/- 5,161
Long-term Liabilities
Capital Lease Obligations 272
Long-term Liabilities  (as reported)59,003
Long-term Liabilities  (calculated)272
+/- 58,731
Total Stockholder Equity
Common Stock5,942
Retained Earnings -304,612
Accumulated Other Comprehensive Income 24,199
Other Stockholders Equity 291,521
Total Stockholder Equity (as reported)17,050
Total Stockholder Equity (calculated)17,050
+/-0
Other
Capital Stock5,942
Cash and Short Term Investments 54,031
Common Stock Shares Outstanding 118,847
Current Deferred Revenue5,161
Liabilities and Stockholders Equity 93,822
Net Debt -53,759
Net Invested Capital 17,050
Net Working Capital 63,252
Property Plant and Equipment Gross 5,558
Short Long Term Debt Total 272



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-312018-06-302017-12-312017-06-302016-12-312016-06-302015-12-312015-06-302014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-312009-06-302008-12-312008-06-302007-12-312007-06-302006-12-312006-06-302005-12-312005-06-302004-12-312004-06-302003-12-312003-06-30
> Total Assets 
7,256
6,489
4,202
3,190
2,566
17,172
14,802
16,751
14,723
19,478
15,020
14,378
12,615
10,994
37,232
33,955
36,438
33,438
9,046
17,075
33,392
29,300
34,656
29,771
62,991
61,545
58,990
55,794
51,308
55,007
47,564
38,885
30,019
0
46,077
0
100,087
0
85,971
0
100,725
92,755
96,194
86,784
83,404
124,037
107,500
94,337
92,711
97,942
93,822
93,82297,94292,71194,337107,500124,03783,40486,78496,19492,755100,725085,9710100,087046,077030,01938,88547,56455,00751,30855,79458,99061,54562,99129,77134,65629,30033,39217,0759,04633,43836,43833,95537,23210,99412,61514,37815,02019,47814,72316,75114,80217,1722,5663,1904,2026,4897,256
   > Total Current Assets 
7,202
6,429
4,162
3,150
2,543
9,668
7,457
9,636
7,452
11,645
6,657
4,418
3,781
1,750
7,411
4,376
6,910
3,900
1,063
9,059
25,074
21,282
27,009
22,234
56,143
53,550
50,186
42,012
33,193
45,547
38,322
29,498
20,753
37,465
37,465
90,697
90,697
76,399
76,399
91,346
91,346
83,129
86,333
76,909
73,449
113,456
96,686
83,680
82,314
87,603
81,021
81,02187,60382,31483,68096,686113,45673,44976,90986,33383,12991,34691,34676,39976,39990,69790,69737,46537,46520,75329,49838,32245,54733,19342,01250,18653,55056,14322,23427,00921,28225,0749,0591,0633,9006,9104,3767,4111,7503,7814,4186,65711,6457,4529,6367,4579,6682,5433,1504,1626,4297,202
       Cash And Cash Equivalents 
6,428
5,093
3,907
2,632
1,755
9,091
6,801
8,824
6,405
10,174
5,661
3,350
3,057
1,131
6,836
3,566
6,486
3,688
950
8,909
19,718
15,890
21,302
16,857
55,768
51,907
47,594
39,012
29,849
42,745
29,336
21,494
11,511
0
13,515
0
10,322
0
27,449
0
71,238
71,469
73,537
59,295
51,565
90,017
54,816
46,731
29,720
58,812
54,031
54,03158,81229,72046,73154,81690,01751,56559,29573,53771,46971,238027,449010,322013,515011,51121,49429,33642,74529,84939,01247,59451,90755,76816,85721,30215,89019,7188,9099503,6886,4863,5666,8361,1313,0573,3505,66110,1746,4058,8246,8019,0911,7552,6323,9075,0936,428
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27
0
0
0
0
5,000
5,000
5,000
2
0
0
0
0
319
0
5,043
5,000
0
20,001
0
40,021
0
10,000
0
10,000
5,000
0
0
0
0
16,328
16,135
20,501
0
0
0020,50116,13516,32800005,00010,000010,000040,021020,00105,0005,0430319000025,0005,0005,0000000270000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72
5,354
166
705
212
373
1,450
2,589
2,711
3,341
1,966
3,986
2,446
3,468
3,518
3,518
38,287
38,287
33,518
33,518
6,504
6,504
3,778
8,487
11,408
13,567
13,096
17,342
12,429
25,321
17,468
18,833
18,83317,46825,32112,42917,34213,09613,56711,4088,4873,7786,5046,50433,51833,51838,28738,2873,5183,5183,4682,4463,9861,9663,3412,7112,5891,4503732127051665,354720000000000000000000
       Other Current Assets 
774
1,336
255
518
788
495
574
812
1,047
1,471
996
1,068
724
619
575
783
397
212
113
78
5,356
226
707
165
373
193
2,592
289
3,344
517
8,986
881
774
0
885
2,067
2,067
1,492
38,950
3,604
3,604
2,882
4,309
6,206
8,317
10,343
24,627
8,385
6,772
11,323
0
011,3236,7728,38524,62710,3438,3176,2064,3092,8823,6043,60438,9501,4922,0672,06788507748818,9865173,3442892,5921933731657072265,356781132123977835756197241,0689961,4711,0478125744957885182551,336774
   > Long-term Assets 
54
60
40
40
23
7,504
7,345
7,115
7,271
7,833
8,363
9,960
8,834
9,244
29,821
29,579
29,528
29,538
7,983
8,016
8,318
8,018
7,647
7,537
6,848
7,995
8,804
13,782
18,115
9,460
9,242
9,387
9,266
0
8,612
0
9,390
0
9,572
0
9,379
9,626
9,861
9,875
9,955
10,581
10,814
10,657
10,397
10,339
12,801
12,80110,33910,39710,65710,81410,5819,9559,8759,8619,6269,37909,57209,39008,61209,2669,3879,2429,46018,11513,7828,8047,9956,8487,5377,6478,0188,3188,0167,98329,53829,52829,57929,8219,2448,8349,9608,3637,8337,2717,1157,3457,5042340406054
       Property Plant Equipment 
54
60
40
40
23
247
156
147
275
399
448
536
396
377
303
288
269
225
181
157
165
218
238
458
462
1,093
1,062
1,375
1,346
1,170
982
921
840
611
611
832
832
1,127
1,127
1,308
1,308
1,535
1,944
1,898
1,851
2,319
2,201
2,101
2,038
1,927
1,813
1,8131,9272,0382,1012,2012,3191,8511,8981,9441,5351,3081,3081,1271,1278328326116118409219821,1701,3461,3751,0621,0934624582382181651571812252692883033773965364483992751471562472340406054
       Goodwill 
0
0
0
0
0
6,380
6,400
6,240
6,240
6,654
7,176
8,611
7,704
8,131
28,479
28,346
28,211
28,342
7,289
7,333
7,733
7,549
7,245
7,077
6,383
6,663
7,499
7,709
7,944
8,029
8,009
8,127
8,104
0
7,692
0
8,237
0
8,125
0
7,763
7,786
7,592
7,653
7,780
7,958
8,009
7,962
7,773
7,835
7,840
7,8407,8357,7737,9628,0097,9587,7807,6537,5927,7867,76308,12508,23707,69208,1048,1278,0098,0297,9447,7097,4996,6636,3837,0777,2457,5497,7337,3337,28928,34228,21128,34628,4798,1317,7048,6117,1766,6546,2406,2406,4006,38000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
301
302
301
301
303
284
284
284
284
284
284
2842842842842842843033013013023010000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
877
789
728
756
780
739
813
734
736
1,039
945
1,048
971
513
526
420
251
164
2
3
6
10
45
37
28
18
64
47
0
34
0
28
0
17
0
7
3
24
23
21
20
320
310
302
293
284
28429330231032020212324370170280340476418283745106321642514205265139711,0489451,03973673481373978075672878987700000
> Total Liabilities 
1,147
1,306
819
846
943
1,485
900
1,044
1,929
1,802
786
935
828
2,103
2,750
1,686
2,073
1,260
981
959
931
1,724
1,527
2,013
926
1,118
1,520
1,610
2,768
2,657
3,603
3,830
2,859
0
25,168
0
72,463
0
76,912
0
77,058
76,395
87,668
82,794
88,144
89,906
85,428
77,747
80,455
77,944
76,772
76,77277,94480,45577,74785,42889,90688,14482,79487,66876,39577,058076,912072,463025,16802,8593,8303,6032,6572,7681,6101,5201,1189262,0131,5271,7249319599811,2602,0731,6862,7502,1038289357861,8021,9291,0449001,4859438468191,3061,147
   > Total Current Liabilities 
1,147
1,306
819
324
706
1,343
853
1,044
1,929
1,802
786
935
828
2,103
2,750
1,686
2,073
1,260
981
959
931
1,724
1,527
2,013
926
1,118
1,520
1,610
2,768
2,657
3,603
3,830
2,859
9,653
9,653
9,233
9,233
25,575
25,575
14,764
14,764
18,397
15,167
15,727
19,558
25,933
21,943
17,764
19,557
18,017
17,769
17,76918,01719,55717,76421,94325,93319,55815,72715,16718,39714,76414,76425,57525,5759,2339,2339,6539,6532,8593,8303,6032,6572,7681,6101,5201,1189262,0131,5271,7249319599811,2602,0731,6862,7502,1038289357861,8021,9291,0448531,3437063248191,3061,147
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
287
0
15
0
341
0
179
131
137
90
52
499
446
180
198
201
179
1792011981804464995290137131179034101502870000000000000000000000000000000000
       Accounts payable 
0
317
0
155
516
405
663
354
1,929
615
786
433
828
626
2,750
345
2,073
450
981
105
931
476
1,527
540
926
207
1,520
528
2,768
462
3,603
1,147
2,859
1,790
6,888
4,711
4,711
2,285
2,285
7,868
7,868
9,236
4,065
7,684
11,700
14,810
3,186
13,246
12,197
11,945
2,629
2,62911,94512,19713,2463,18614,81011,7007,6844,0659,2367,8687,8682,2852,2854,7114,7116,8881,7902,8591,1473,6034622,7685281,5202079265401,5274769311059814502,0733452,7506268284337866151,92935466340551615503170
       Other Current Liabilities 
1,147
989
819
169
190
938
190
690
0
1,187
0
502
0
1,477
0
1,341
0
810
0
511
0
955
0
1,176
0
911
0
1,082
0
2,195
0
2,683
0
2,478
5,098
4,507
15
17,042
5,907
6,717
6,717
9,030
6,718
7,953
7,806
10,624
9,447
4,338
7,162
0
9,800
9,80007,1624,3389,44710,6247,8067,9536,7189,0306,7176,7175,90717,042154,5075,0982,47802,68302,19501,082091101,17609550511081001,34101,477050201,18706901909381901698199891,147
   > Long-term Liabilities 
0
317
0
522
237
142
47
354
1,929
615
786
433
828
626
2,750
345
2,073
450
981
448
931
769
1,527
837
926
207
1,520
528
2,768
462
3,603
1,147
2,859
0
15,515
0
63,230
0
51,337
0
62,294
57,998
72,501
67,067
68,586
63,973
63,485
59,983
60,898
59,927
59,003
59,00359,92760,89859,98363,48563,97368,58667,06772,50157,99862,294051,337063,230015,51502,8591,1473,6034622,7685281,5202079268371,5277699314489814502,0733452,7506268284337866151,9293544714223752203170
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,515
15,515
63,230
63,230
51,337
51,337
62,294
62,294
57,998
72,501
67,067
68,586
63,973
63,485
0
60,732
0
0
0060,732063,48563,97368,58667,06772,50157,99862,29462,29451,33751,33763,23063,23015,51515,515000000000000000000000000000000000
> Total Stockholder Equity
6,109
5,183
3,383
2,344
1,623
15,687
13,902
15,707
12,794
17,676
14,234
13,443
11,787
8,891
34,482
32,269
34,365
32,178
8,065
16,116
32,461
27,576
33,129
27,758
62,065
60,427
57,470
54,184
48,540
52,350
43,961
35,055
27,160
0
20,909
0
27,624
0
9,059
0
23,667
16,360
8,526
3,990
-4,740
34,131
22,072
16,590
12,256
19,998
17,050
17,05019,99812,25616,59022,07234,131-4,7403,9908,52616,36023,66709,059027,624020,909027,16035,05543,96152,35048,54054,18457,47060,42762,06527,75833,12927,57632,46116,1168,06532,17834,36532,26934,4828,89111,78713,44314,23417,67612,79415,70713,90215,6871,6232,3443,3835,1836,109
   Common Stock
238
239
238
239
239
903
930
1,131
1,132
1,199
1,199
1,199
1,349
1,350
2,799
2,799
5,766
5,771
5,771
1,872
2,351
2,353
2,600
2,605
3,490
3,490
3,490
3,490
3,499
3,500
3,504
3,554
3,608
3,919
3,919
4,141
4,141
4,165
4,165
4,487
4,487
4,489
4,489
4,489
4,491
5,384
5,390
5,403
5,512
5,800
5,942
5,9425,8005,5125,4035,3905,3844,4914,4894,4894,4894,4874,4874,1654,1654,1414,1413,9193,9193,6083,5543,5043,5003,4993,4903,4903,4903,4902,6052,6002,3532,3511,8725,7715,7715,7662,7992,7991,3501,3491,1991,1991,1991,1321,131930903239239238239238
   Retained Earnings -304,612-290,605-282,762-272,411-263,263-249,644-242,557-230,646-222,966-213,550-203,683-203,683-184,215-184,215-162,913-162,913-151,999-151,999-141,308-133,777-125,098-116,428-122,033-115,950-113,163-109,435-107,099-102,958-97,494-91,870-86,294-82,928-81,029-57,772-57,257-53,831-52,203-45,150-41,632-38,057-35,527-30,625-28,889-25,589-23,128-21,764-18,900-18,179-17,018-15,219-14,292
   Capital Surplus 000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
20,163
20,163
20,163
20,284
20,284
36,548
36,100
40,165
40,551
47,102
48,562
50,301
52,070
52,691
83,886
83,301
85,856
84,179
83,323
72,601
116,404
92,230
128,023
103,949
165,674
142,826
167,143
0
167,074
0
165,555
0
164,860
30,839
30,839
186,396
186,396
35,375
192,504
38,549
198,849
201,389
203,214
206,280
209,355
253,915
255,612
259,304
265,362
280,600
291,521
291,521280,600265,362259,304255,612253,915209,355206,280203,214201,389198,84938,549192,50435,375186,396186,39630,83930,839164,8600165,5550167,0740167,143142,826165,674103,949128,02392,230116,40472,60183,32384,17985,85683,30183,88652,69152,07050,30148,56247,10240,55140,16536,10036,54820,28420,28420,16320,16320,163



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue25,375
Cost of Revenue-10,318
Gross Profit15,05715,057
 
Operating Income (+$)
Gross Profit15,057
Operating Expense-64,661
Operating Income-49,604-49,604
 
Operating Expense (+$)
Research Development44,025
Selling General Administrative20,636
Selling And Marketing Expenses0
Operating Expense64,66164,661
 
Net Interest Income (+$)
Interest Income1,446
Interest Expense-34
Other Finance Cost-0
Net Interest Income1,412
 
Pretax Income (+$)
Operating Income-49,604
Net Interest Income1,412
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-50,310-47,486
EBIT - interestExpense = -48,192
-50,310
-43,233
Interest Expense34
Earnings Before Interest and Taxes (EBIT)-48,158-50,276
Earnings Before Interest and Taxes (EBITDA)-47,660
 
After tax Income (+$)
Income Before Tax-50,310
Tax Provision--7,043
Net Income From Continuing Ops-43,267-43,267
Net Income-43,267
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses74,979
Total Other Income/Expenses Net-2,118-1,412
 

Technical Analysis of Silence Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Silence Therapeutics PLC. The general trend of Silence Therapeutics PLC is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Silence Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Silence Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 21.94 < 27.72.

The bearish price targets are: 19.98 > 16.64 > 16.20.

Tweet this
Silence Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Silence Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Silence Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Silence Therapeutics PLC. The current macd is -0.37211285.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Silence Therapeutics PLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Silence Therapeutics PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Silence Therapeutics PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Silence Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartSilence Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Silence Therapeutics PLC. The current adx is 22.68.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Silence Therapeutics PLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Silence Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Silence Therapeutics PLC. The current sar is 26.63.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Silence Therapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Silence Therapeutics PLC. The current rsi is 40.63. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Silence Therapeutics PLC Daily Relative Strength Index (RSI) ChartSilence Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Silence Therapeutics PLC. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Silence Therapeutics PLC price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Silence Therapeutics PLC Daily Stochastic Oscillator ChartSilence Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Silence Therapeutics PLC. The current cci is -112.79355237.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Silence Therapeutics PLC Daily Commodity Channel Index (CCI) ChartSilence Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Silence Therapeutics PLC. The current cmo is -31.80903649.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Silence Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartSilence Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Silence Therapeutics PLC. The current willr is -92.1686747.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Silence Therapeutics PLC Daily Williams %R ChartSilence Therapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Silence Therapeutics PLC.

Silence Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Silence Therapeutics PLC. The current atr is 1.59083228.

Silence Therapeutics PLC Daily Average True Range (ATR) ChartSilence Therapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Silence Therapeutics PLC. The current obv is 956,433.

Silence Therapeutics PLC Daily On-Balance Volume (OBV) ChartSilence Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Silence Therapeutics PLC. The current mfi is 36.48.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Silence Therapeutics PLC Daily Money Flow Index (MFI) ChartSilence Therapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Silence Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Silence Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Silence Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.626
Ma 20Greater thanMa 5023.895
Ma 50Greater thanMa 10022.573
Ma 100Greater thanMa 20018.386
OpenGreater thanClose22.090
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Silence Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Silence Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Silence Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Silence Therapeutics PLC

I send you an email if I find something interesting about Silence Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Silence Therapeutics PLC.

Receive notifications about Silence Therapeutics PLC in your mailbox!